

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA

DAVID CODELL PRIDE, JR.,

Plaintiff,

v.

DR. STRAGA,

Defendant.

Case No.: 14-CV-414 JLS (DHB)

**ORDER GRANTING DEFENDANT’S
MOTION TO DISMISS**

(ECF No. 45)

Presently before the Court is Defendant Dr. Straga’s Motion to Dismiss Third Amended Complaint, (“MTD,” ECF No. 45). Also before the Court are Plaintiff David Codell Pride Jr.’s Response in Opposition to, (“Opp’n,” ECF No. 46), and Defendant’s Reply in Support of, (“Reply,” ECF No. 47), Defendant’s MTD. The Court vacated the hearing on the motion and took the matter under submission pursuant to Civil Local Rule 7.1(d)(1). (ECF No. 40.) After considering the parties’ arguments and the law, the Court **GRANTS** Defendant’s MTD, (ECF No. 45), and **DISMISSES WITHOUT PREJUDICE** Plaintiff’s Third Amended Complaint.

///
///
///

1 **BACKGROUND**

2 Plaintiff is currently an inmate at Richard J. Donovan Correctional Facility in
3 California. (First Am. Compl. (“FAC”) 1, ECF No. 6.)¹ The events underlying this
4 claim occurred while Plaintiff was an inmate at Calipatria State Prison (“CSP”), also in
5 California. (*Id.*) In 2009, Plaintiff was taking Tramadol prescribed to him by his primary
6 care physician at CSP for chronic knee, neck, back, and shoulder pain. (*Id.* at 3.) On
7 February 24, 2009, Plaintiff was taken off Tramadol and prescribed Neurontin by
8 Defendant, a neurologist treating Plaintiff. (Third Am. Compl. (“TAC”) ¶ 6, ECF No.
9 44.)²

10 After the initial appointment, Plaintiff had several more primary care appointments
11 with Dr. Straga between February 2009 and July 2010. (*Id.* ¶ 7.) Plaintiff informed Dr.
12 Straga during these visits that the Neurontin was not relieving his chronic pain. (*Id.* ¶ 8.)
13 There are no further factual allegations that illuminate what happened concerning
14 Plaintiff’s treatment after July 2010. From those factual allegations, Plaintiff concludes
15 that Defendant knew the Neurontin treatment regimen provided Plaintiff no relief. (*Id.*
16 ¶ 11.) Plaintiff also alleges that Defendant failed to provide treatment, “[d]espite the
17 diagnose [sic] of central neuropathic pain, and repeated complaints by plaintiff and
18 request [sic] for a different method of treatment which would have brought his pain and
19 treatment needs to an acceptable level of care.” (*Id.* ¶¶ 12–13.)

20 Plaintiff now brings a claim under 42 U.S.C. § 1983 alleging that Defendant
21 violated his Eighth Amendment right. (*Id.* ¶ 18.)

22 ///
23 ///

24 _____
25 ¹ The Court recites these background facts from Plaintiff’s First Amended Complaint, rather than his
26 present Third Amended Complaint, because he omits these details from his Third Amended Complaint.

27 ² It does not appear that Plaintiff filed a Second Amended Complaint. He labeled his most recent
28 complaint: “Third Amended Complaint for Damages.” (ECF No. 44.) The Court will refer to the
complaint currently pending as Plaintiff’s Third Amended Complaint, or TAC, even though it is only the
second amended complaint.

1 **LEGAL STANDARD**

2 Federal Rule of Civil Procedure 12(b)(6) permits a party to raise by motion the
3 defense that the complaint “fail[s] to state a claim upon which relief can be granted,”
4 generally referred to as a motion to dismiss. The Court evaluates whether a complaint
5 states a cognizable legal theory and sufficient facts in light of Federal Rule of Civil
6 Procedure 8(a), which requires a “short and plain statement of the claim showing that the
7 pleader is entitled to relief.” Although Rule 8 “does not require ‘detailed factual
8 allegations,’ . . . it [does] demand more than an unadorned, the-defendant-unlawfully-
9 harmed-me accusation.” *Ashcroft v. Iqbal*, 556 U.S. 662, 678 (2009) (quoting *Bell Atl.*
10 *Corp. v. Twombly*, 550 U.S. 544, 555 (2007)). In other words, “a plaintiff’s obligation to
11 provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more than labels and
12 conclusions, and a formulaic recitation of the elements of a cause of action will not do.”
13 *Twombly*, 550 U.S. at 555 (citing *Papasan v. Allain*, 478 U.S. 265, 286 (1986)). A
14 complaint will not suffice “if it tenders ‘naked assertion[s]’ devoid of ‘further factual
15 enhancement.’” *Iqbal*, 556 U.S. at 677 (citing *Twombly*, 550 U.S. at 557).

16 In order to survive a motion to dismiss, “a complaint must contain sufficient
17 factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’”
18 *Id.* (quoting *Twombly*, 550 U.S. at 570); *see also* Fed. R. Civ. P. 12(b)(6). A claim is
19 facially plausible when the facts pled “allow the court to draw the reasonable inference
20 that the defendant is liable for the misconduct alleged.” *Iqbal*, 556 U.S. at 677 (citing
21 *Twombly*, 550 U.S. at 556). That is not to say that the claim must be probable, but there
22 must be “more than a sheer possibility that a defendant has acted unlawfully.” *Id.* Facts
23 “‘merely consistent with’ a defendant’s liability” fall short of a plausible entitlement to
24 relief. *Id.* (quoting *Twombly*, 550 U.S. at 557). Further, the Court need not accept as true
25 “legal conclusions” contained in the complaint. *Id.* This review requires context-specific
26 analysis involving the Court’s “judicial experience and common sense.” *Id.* at 679
27 (citation omitted). “[W]here the well-pleaded facts do not permit the court to infer more
28 than the mere possibility of misconduct, the complaint has alleged—but it has not

1 ‘show[n]’—‘that the pleader is entitled to relief.’” *Id.*

2 In the wake of the heightened pleading standard announced in *Twombly* and
3 affirmed in *Iqbal*, the Court remains obligated, “where the petitioner is pro se,
4 particularly in civil rights cases, to construe the pleadings liberally and to afford the
5 petitioner the benefit of any doubt.” *Hebbe v. Pliler*, 627 F.3d 338, 342 (9th Cir. 2010)
6 (quoting *Bretz v. Kelman*, 773 F.2d 1026, 1027 n.1 (9th Cir. 1985) (en banc)). However,
7 the Court may not “supply essential elements of claims that were not initially pled.” *Ivey*
8 *v. Bd. of Regents of the Univ. of Alaska*, 673 F.2d 266, 268 (9th Cir. 1982). And “vague
9 and conclusory allegations of official participation in civil rights violations” are not
10 “sufficient to withstand a motion to dismiss.” *Id.*

11 Where a complaint does not survive 12(b)(6) analysis, the Court will grant leave to
12 amend unless it determines that no modified contention “consistent with the challenged
13 pleading . . . [will] cure the deficiency.” *DeSoto v. Yellow Freight Sys., Inc.*, 957 F.2d
14 655, 658 (9th Cir. 1992) (quoting *Schriber Distrib. Co. v. Serv-Well Furniture Co.*, 806
15 F.2d 1393, 1401 (9th Cir. 1986)).

16 ANALYSIS

17 I. Eighth Amendment Standard

18 An inmate has an Eighth Amendment right to adequate physical and mental health
19 care. *Doty v. Cnty. of Lassen*, 37 F.3d 540, 546 (9th Cir. 1994). “To establish
20 unconstitutional treatment of a medical condition . . . a prisoner must show deliberate
21 indifference to a “serious” medical need. *Id.* (citing *McGuckin v. Smith*, 974 F.2d 1050,
22 1059 (9th Cir. 1992)). Deliberate indifference to the serious medical needs of an inmate
23 is inconsistent with the basic standards of human decency and antithetical to the Eighth
24 Amendment’s proscription of “unnecessary and wanton infliction of pain.” *Gregg v.*
25 *Georgia*, 428 U.S. 153, 173 (1976).

26 A determination of deliberate indifference to a serious medical need involves a
27 two-step analysis consisting of both objective and subjective inquiries. *Farmer v.*
28 *Brennan*, 511 U.S. 825, 837 (1994). First, the plaintiff must demonstrate a serious

1 medical need such that failure to provide treatment could “result in further significant
2 injury” or “unnecessary and wanton infliction of pain.” *Jett v. Penner*, 439 F.3d 1091,
3 1096 (9th Cir. 2006) (quoting *Estelle v. Gamble*, 429 U.S. 97, 104 (1976)). Second, the
4 plaintiff must show that the defendant’s response to the medical need was deliberately
5 indifferent. *Id.* (citing *McGuckin*, 974 F.2d at 1059–60).

6 Deliberate indifference consists of (1) a purposeful act or failure to respond to a
7 prisoner’s pain or possible medical need and (2) harm caused by the indifference. *Id.*
8 Such indifference may be manifested when “prison officials deny, delay[,] or
9 intentionally interfere with medical treatment, or it may be shown by the way in which
10 prison physicians provide medical care.” *Hutchinson v. United States*, 838 F.2d 390, 394
11 (9th Cir. 1988). This standard is one of subjective recklessness. *Farmer*, 511 U.S. at
12 839–40. “To satisfy this subjective component of deliberate indifference, the inmate
13 must show that prison officials ‘kn[e]w [] of and disregard[ed]’ the substantial risk of
14 harm, but the officials need not have intended any harm to befall the inmate; ‘it is enough
15 that the official acted or failed to act despite his knowledge of a substantial risk of serious
16 harm.’” *Lemire v. Cal. Dep’t of Corr. & Rehab.*, 726 F.3d 1062, 1074 (9th Cir. 2013)
17 (alterations in original) (quoting *Farmer*, 511 U.S. at 837, 842). “Deliberate indifference
18 is a high legal standard. A showing of medical malpractice or negligence is insufficient
19 to establish a constitutional deprivation under the Eighth Amendment.” *Hamby v.*
20 *Hammond*, 821 F.3d 1085, 1092 (9th Cir. 2016) (quoting *Toguchi v. Chung*, 391 F.3d
21 1051, 1060 (9th Cir. 2004)); see *Estelle*, 429 U.S. at 106.

22 **II. Application**

23 **A. Serious Medical Need**

24 Accepting his factual allegations as true, Plaintiff sufficiently pleads a serious medical
25 need. Plaintiff alleges he suffered from chronic pain throughout his body, bulging and
26 ruptured discs, and nerve pain, among other maladies. (TAC ¶ 4.)

27 ///

28 ///

1 ***B. Deliberate Indifference***

2 The Court turns to the second element, deliberate indifference. Plaintiff alleges
3 that during his appointments with Defendant he complained to Defendant that she
4 “purposefully failed to provide plaintiff with treatment that was effective in meeting his
5 treatment needs with a regiment [sic] of care that was adequate in treating his medical
6 needs and relieving his chronic pain, and which met community standards.” (*Id.* ¶ 8.) In
7 sum, Plaintiff believes his treatment was ineffective, (*see id.* ¶ 11 (“Defendant Straga
8 failed to afford plaintiff with treatment that was effective.”)), and inadequate to relieve
9 his chronic pain, (*see id.* ¶ 12 (“[Defendant] failed to provide treatment which reduced or
10 relived [sic] plaintiff’s medical needs.”)).

11 Defendant argues that her decision to discontinue Tramadol in favor of Neurontin
12 is simply a difference of opinion and is not actionable.³ (MTD 5.) Defendant states that
13 Plaintiff does not allege that Dr. Straga refused to provide any pain medication, but rather
14 Plaintiff was critical of the specific medication prescribed, i.e., he did not want
15 Neurontin, but did want a different drug. (*Id.*)

16 Generally, difference of medical opinion . . . [is] insufficient, as a matter of law, to
17 establish deliberate indifference.” *Toguchi*, 391 F.3d at 1058 (alteration in original)
18 (quoting *Jackson v. McIntosh*, 90 F.3d 330, 332 (9th Cir. 1996)). However, the choice to
19 pursue one treatment among alternatives may support a deliberate indifference claim if
20 the elected course of treatment “was medically unacceptable under the circumstances”
21 and was chosen in “conscious disregard of an excessive risk to the prisoner’s health.”
22 *Jackson*, 90 F.3d at 332 (declining to grant summary judgment for doctors where the
23

24 ³ Defendant also argues Plaintiff’s Third Amended Complaint omits several critical allegations,
25 previously included in the First Amended Complaint, that are important to the context of Plaintiff’s
26 claims. (MTD 2.) For example, the TAC omits Plaintiff’s previous factual allegation that his Neurontin
27 prescription was discontinued in July 2010 due to patient compliance issues. (*Id.*; FAC 29.) Nor did
28 Defendant’s care end in July 2010—Plaintiff previously alleged that he had follow up visits with
Defendant and was prescribed other treatment regimes by Defendant. (MTD 2–3; FAC 29–31.) The
Court understands Defendant’s concern, but concludes that Plaintiff’s claim fails as a matter of law
without considering the omitted context between Plaintiff’s First and Third Amended Complaints.

1 plaintiff alleged they denied him a kidney transplant out of personal animosity).

2 *1. Whether the Elected Course of Treatment Was Medically Unacceptable*

3 Plaintiff argues that he will be able to show that the FDA did not approve
4 prescribing Neurontin for treatment of symptoms associated with central neuropathic pain
5 and thus his treatment was medically unacceptable. (Opp'n 7.) His theory is predicated
6 on a district court opinion in *In re Neurontin Mktg. & Sales Practices Litig.*, 799 F. Supp.
7 2d 110 (D. Mass. 2011), which purportedly held that Neurontin is not effective at
8 relieving nerve pain. (Opp'n 8.)

9 That case concerned Pfizer's fraudulent marketing of Neurontin for off-label uses.
10 *See In re Neurontin*, 799 F. Supp. 2d at 112. As part of its finding of fact, the district
11 court made several findings concerning Neurontin's efficacy for off-label uses, including
12 neuropathic pain. *See In re Neurontin Mktg. & Sales Practices Litig.*, No. 04-cv-10739-
13 FBS, 2011 WL 3852254, at *34 (D. Mass. Aug. 31, 2011). Specifically, the court found
14 that

15 there is no reliable scientific evidence that Neurontin is
16 effective for bipolar disorder, migraine, or at high doses. With
17 respect to some kinds of neuropathic pain, there is some
18 scientific evidence of efficacy. However, as the FDA found,
19 there is no reliable scientific evidence to support a broad
20 indication of neuropathic pain.

20 *Id.* The court went on to discuss several double-blind, randomized, control trials
21 assessing Neurontin's off-label efficacy for neuropathic pain. The court found:

22 After a review of 12 [double blind trials] studying the use of
23 Neurontin in the treatment of neuropathic pain, and a careful
24 consideration of the expert testimony, the Court finds that there
25 is no generally accepted scientific evidence that Neurontin is
26 effective in the treatment of neuropathic pain as a broad
27 category or indication. This is a closer call because, unlike
28 migraine and bipolar disorder, there are four [double-blind
trials] that concluded that Neurontin was better than placebo for
treating certain narrow indications like postamputation phantom
limb pain, neuropathic pain after spinal cord injury, and

1 Complex Regional Pain Syndrome I. . . . However, using the
2 generally accepted standard of scientific efficacy followed by
3 the FDA and the scientific community (requiring two [double-
4 blind trials] that demonstrate efficacy), the Court is persuaded
5 that there is insufficient reliable evidence of the efficacy of
Neurontin with respect to the broad indication of neuropathic
pain.

6 *Id.* at *43.

7 The findings of fact in *In re Neurontin Marketing & Sales Practices Litigation* do
8 suggest that Plaintiff has a point that Neurontin’s off-label efficacy is not conclusive.
9 However, Plaintiff’s reliance on this one case sweeps too broadly. The finding of fact
10 was made with respect to a “broad indication of neuropathic pain.” *Id.* This does not
11 speak to the circumstances as they apply to Plaintiff’s own medical situation.

12 Further, the district court did note that Neurontin did have some efficacy with
13 respect to some kinds of neuropathic pain. *Id.* at *34. The court stated that its finding
14 was a close call because there were four double-blind trials that concluded “Neurontin
15 was better than placebo for treating certain narrow indications like postamputation
16 phantom limb pain, neuropathic pain after spinal cord injury, and Complex Regional Pain
17 Syndrome I.”⁴ *Id.* at *43. The primary issue with relying on a case like *In re Neurontin*
18 *Marketing & Sales Practices Litigation* is that the district court’s conclusions speak to the
19 broad contours of Neurontin efficacy (or lack thereof) but those conclusions do not take
20 into account the particulars of Plaintiff’s medical situation. The Court finds Plaintiff has
21 not alleged sufficient facts to show how the elected course of treatment was medically
22 unacceptable.

23 ///

24
25 ⁴ Further, it appears that at the time of Plaintiff’s treatment Neurontin was approved by the California
26 Department of Corrections and Rehabilitation (“CDCR”), but removed from CDCR’s formulary after
27 2011. See *Haney v. Nangalama*, No. 11-cv-1218-MCE-CMK-P, 2013 WL 4482866, at *1 (E.D. Cal.
28 Aug. 20, 2013); *Johnson v. Sepulveda*, No. 11-cv-6693-JST (PR), 2013 WL 5313133, at *1–2 (N.D.
Cal. Sept. 23, 2013). While this does undercut the scientific argument for Neurontin’s efficacy, it
bolsters Defendant’s position because Defendant was prescribing a course of treatment approved by
CDCR at the time of Plaintiff’s allegations.

1 2. *Whether Defendant Consciously Disregarded Excessive Risk to Plaintiff's*
2 *Health*

3 “To satisfy this subjective component of deliberate indifference, the inmate must
4 show that prison officials ‘kn[e]w [] of and disregard[ed]’ the substantial risk of harm,
5 but the officials need not have intended any harm to befall the inmate; ‘it is enough that
6 the official acted or failed to act despite his knowledge of a substantial risk of serious
7 harm.’” *Lemire*, 726 F.3d at 1074 (alteration in original) (quoting *Farmer*, 511 U.S. at
8 837, 842). In *Farmer*, the Supreme Court held that

9 a prison official cannot be found liable under the Eighth
10 Amendment for denying an inmate humane conditions of
11 confinement unless the official knows of and disregards an
12 excessive risk to inmate health or safety; the official must both
13 be aware of facts from which the inference could be drawn that
14 a substantial risk of serious harm exists, and he must also draw
15 the inference.

14 511 U.S. at 837.

15 Here, the only allegation Plaintiff puts forward is that during his appointments with
16 Defendant he complained to her about the treatment. (*See* TAC ¶ 8.) There are no
17 factual allegations that Defendant knew of an excessive risk. There are no factual
18 allegations that, with the knowledge of the excessive risk to Plaintiff, Defendant
19 disregarded that risk. For example, in his TAC Plaintiff fails to allege any facts as to
20 what happened after July 2010. (*See id.* ¶ 7.) Even assuming, for the sake of argument,
21 Defendant knew Neurontin constituted an excessive risk to Plaintiff’s medical condition,
22 Plaintiff omits any factual allegations as to what Defendant did or did not do after
23 receiving his complaints.

24 In his opposition, Plaintiff seems to suggest that Defendant’s action was punitive
25 because Defendant viewed Plaintiff as a “Complainer.” (Opp’n 7 (“Plaintiff will offer
26 evidence that Dr. Straga often labelled [sic] plaintiff as a “Complainer” and because she
27 viewed plaintiff as a “Complainer,” she deliberately prescribed a Treatment Plan that
28 provided ineffective treatment for his chronic pain.”).) This argument fails for two

1 reasons. First, factual allegations must be included in a complaint and not contained in
2 an opposition brief. *Schneider v. Cal. Dep't of Corr.*, 151 F.3d 1194, 1197 n.1 (9th Cir.
3 1998) (“[I]n determining the propriety of a Rule 12(b)(6) dismissal, a court may not look
4 beyond the complaint to a plaintiff’s moving papers, such as a memorandum in
5 opposition to a defendant’s motion to dismiss.”). Second, there are no allegations
6 connecting Defendant purportedly labeling Plaintiff a “complainer” to his allegedly
7 deficient medical treatment.

8 Thus, Plaintiff has not alleged sufficient facts to allow the Court to infer that
9 Defendant consciously disregarded an excessive risk to Plaintiff.

10 In sum, this is a difference of opinion between a physician and a prisoner, which is
11 insufficient as a matter of law to establish deliberate indifference. The crux of Plaintiff’s
12 complaint is that Defendant substituted Neurontin for his previously subscribed Tramadol
13 and then he was treated with Neurontin from February 2009 to July 2010. (TAC ¶¶ 6–7.)
14 There are no further factual allegations, only conclusory statements like Defendant
15 “failed to provide treatment which reduced or relived [sic] plaintiff’s medical needs.”
16 (*Id.* ¶ 11.) Plaintiff previously alleged more detailed factual allegations, (*see generally*
17 FAC), but chose to include significantly less detail in his TAC. Accordingly, the Court
18 **GRANTS** Defendant’s MTD, (ECF No. 45).

19 CONCLUSION

20 For the reasons stated above, the Court **GRANTS** Defendant’s MTD (ECF No.
21 45). The Court continues to harbor serious doubts that Plaintiff will be able to adequately
22 re-plead his claims against Defendant. However, because Plaintiff is a prisoner,
23 proceeding pro se, and alleging a civil rights claim the Court will allow amendment. *See*
24 *Hebbe*, 627 F.3d at 342; *DeSoto*, 957 F.2d at 658. Accordingly, the Court **DISMISSES**
25 **WITHOUT PREJUDICE** Plaintiff’s Third Amended Complaint.

26 ///


27 ///

28 ///

1 Plaintiff **SHALL FILE** an amended complaint, if any, on or before thirty (30) days on
2 the date this Order is electronically docketed. *Failure to file an amended complaint by*
3 *this date may result in Plaintiff's Eighth Amendment claims being dismissed with*
4 *prejudice.*

5 **IT IS SO ORDERED.**

6 Dated: April 10, 2018

7 
8 Hon. Janis L. Sammartino
9 United States District Judge
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28